menu search

Why shares of scilex are up monday

Last week, the company said it is hiring a firm to look into manipulation of its stock. The company just got approval in February from the FDA for acu...

October 9, 2023, 2:55 pm

Us judge overturns eli lilly's $176.5 million loss in teva patent case

Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found...

September 26, 2023, 4:34 pm

Acute migraine treatment market predicted to reach usd 7 billion by 2031, recording over a 15% cagr says, transparency market research

There are several drugs and therapies available for treating acute migraines, which is a rapidly expand...

August 18, 2023, 10:30 am

Abbvie (abbv) gets eu approval for migraine prevention drug

Following the approval, AbbVie's (ABBV) Aquipta is the first and the only oral CGRP receptor antagonist approved in the EU to prevent episodic and chr...

August 17, 2023, 1:17 pm

Tonix pharmaceuticals completes acquisition of two fda-approved, marketed migraine products

Strategic Acquisition Helps Build Tonix’s Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of F...

July 3, 2023, 11:00 am

Abbvie (abbv) gets chmp positive opinion for atogepant approval

AbbVie (ABBV) receives a positive recommendation from the European Union's medicinal products committee for the approval of its ...

June 26, 2023, 12:46 pm

Lilly's (lly) migraine drug fails vis-a-vis pfizer's nurtec odt

Results from a post-approval study show that treatment with Lilly's (LLY) Emgality failed to achieve statistical superiority over Pfizer's Nurtec ODT ...

June 19, 2023, 12:29 pm

Eli lilly's migraine drug fails to meet main goal in post-approval study

Eli Lilly said on Friday its drug Emgality did not meet the primary goal of superiority to Pfizer Inc's Nurtec ODT in prevention of episodic ...

June 16, 2023, 12:28 pm

Scilex holding company to present data on elyxyb™ (celecoxib oral solution) at the 65th annual scientific meeting of the american headache society, in austin, tx.

PALO ALTO, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Ther...

June 16, 2023, 9:00 am

Post-operative pain management market size to hit usd 4.59 billion by 2030 at 6.8% cagr – report by market research future (mrfr)

Post-Operative Pain Management Market Trends And Insights By Pain Type (Acute Pain, Moderate Pain, Severe Pain), By Products (Non-Steroidal Anti-Infla...

May 25, 2023, 7:20 pm

Pulmatrix selected to present at the annual biotechnology innovation organization (bio) international convention

Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute ...

May 24, 2023, 9:05 am

Vivos therapeutics reports positive results from migraine study; shares skyrocket

Vivos Therapeutics (NASDAQ:VVOS) said its recently acquired Preventive Oral Device, known as POD, has been shown to treat and prevent headaches in a ...

May 1, 2023, 8:53 am

Lundbeck to present broad range of data on migraine and brain health at 75th annual meeting of the american academy of neurology

DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck to Present Broad Range of Data on migraine and Brain Health ...

April 17, 2023, 8:00 am

Tonix pharmaceuticals expedites fibromyalgia and chronic migraine programs

Streamlining Phase 3 Fibromyalgia and Phase 2 Chronic migraine Trials by Eliminating Interim Analyses T...

April 13, 2023, 11:00 am

Can this new drug boost pfizer's stock?

Zavzpret is a nasal spray for treating acute migraine in adults. It could net the drug giant more than ...

March 25, 2023, 9:45 am

Royalty pharma raises fy2023 guidance after $475m pfizer milestone payment

Royalty Pharma plc announced that it is raising its full year 2023 Adjusted Cash Receipts (non-GAAP) guidance to between $2.85 billion and $2.95 bill...

March 15, 2023, 11:42 am

Pfizer (pfe) gets fda nod for migraine nasal spray zavzpret

Zavzpret (zavegepant) is now part of Pfizer's (PFE) migraine drugs portfolio with the 2022 acquisition ...

March 13, 2023, 12:58 pm

A new migraine medication is coming this summer — and it promises relief in just 15 minutes

The Food and Drug Administration approved Zavzpret, a nasal spray from Pfizer, on Friday. The medication is expected to hit shelves this July....

March 11, 2023, 12:50 pm

Us fda approves pfizer’s nasal spray for migraine

(Reuters) -The U.S. Food and Drug Administration on Friday approved Pfizer Inc’s nasal spray for migraine...

March 10, 2023, 5:31 pm

U.s. fda approves pfizer’s nasal spray for migraine

(Reuters) -The U.S. Food and Drug Administration on Friday approved Pfizer Inc’s nasal spray for migraine...

March 10, 2023, 1:06 pm


Search within

Pages Search Results: